CTOs on the Move

Pittsburgh Tissue Engineering Initiative

www.ptei.org

 
Pittsburgh Tissue Engineering Initiative is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ptei.org
  • 100 Technology Dr Ste 200
    Pittsburgh, PA USA 15219
  • Phone: 412.395.4200

Executives

Name Title Contact Details

Similar Companies

Dearborn County Hospital

Dearborn County Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Dearborn County Hospital is based in Lawrenceburg, IN. You can find more information on Dearborn County Hospital at www.dch.org

Peninsula Community Mental Health Center

Peninsula Community Mental Health Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Peninsula Community Mental Health Center is based in Port Angeles, WA. You can find more information on Peninsula Community Mental Health Center at www.pcmhc.org

Tekran

Tekran Inc. is a Scarborough, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pacific Hospitalist Associates

Pacific Hospitalist Associates is a Newport Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.